Results 101 to 110 of about 231,111 (314)

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Human papillomavirus infection mechanism and vaccine of vulva carcinoma

Open Life Sciences, 2016
Vulvar carcinoma is a rare tumor occurring in female patients. Though more than 40% of vulva cancers are due to the infection of human papillomavirus (HPV), understanding of HPV and vulvar carcinoma is insufficient.
Tong Qing, Zheng Lingqi, Zhao Ruiying, Xing Tianling, Li Yunbo, Lin Tong, Zhang Xuan, Jin Zhe   +7 more
doaj   +1 more source

Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy. [PDF]

, 2019
Natural killer (NK) cells of the innate immune system are a key focus of research within the field of immuno-oncology based on their ability to recognize and eliminate malignant cells without prior sensitization or priming.
Canter, Robert J, Gingrich, Alicia A, Modiano, Jaime F   +2 more
core   +2 more sources

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. [PDF]

, 2019
Background: The colorectal cancer antigen GUCY2C exhibits unique split tolerance, evoking antigen-specific CD8+, but not CD4+, T-cell responses that deliver anti-tumor immunity without autoimmunity in mice.
Abraham, Tara S., Baybutt, Trevor R., Flickinger, John C., Hyslop, Terry, Kraft, Walter K., Sato, Takami, Snook, Adam E., Waldman, Scott A., Xiang, Bo, Zhan, Tingting   +9 more
core   +3 more sources

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

FGFR Like1 drives esophageal cancer progression via EMT, PI3K/Akt, and notch signalling: insights from clinical data and next‐generation sequencing analysis

FEBS Open Bio, EarlyView.
Clinical analysis reveals significant dysregulation of FGFRL1 in esophageal cancer (EC) patients. RNAi‐coupled next‐generation sequencing (NGS) and in vitro study reveal FGFRL1‐mediated EC progression via EMT, PI3K/Akt, and Notch pathways. Functional assays confirm its role in tumor growth, migration, and invasion.
Aprajita Srivastava, Anoop Saraya, Deepak Gunjan, Rinu Sharma   +3 more
wiley   +1 more source

Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial

Nature Communications
Combining immunotherapy with chemoradiation is effective in locally advanced cervical cancer. However, the impact of induction combination immunotherapy on immune modulation and treatment response is poorly understood. In this phase II trial (NCT04256213)
Isabelle Ray-Coquard, Marie-Christine Kaminsky-Forrett, Ryotaro Ohkuma, Aymeric de Montfort, Florence Joly, Isabelle Treilleux, Sarah Ghamry-Barrin, Diana Bello-Roufai, Pierre Saintigny, Antoine Angelergues, Lucas Michon, Anne-Claire Hardy-Bessard, Valéry Attignon, Jessie Auclair, Gabriel Chemin, Alexandra Lainé, Hélène Péré, David Veyer, Aude-Marie Savoye, Justine Berthet, Christophe Caux, Fabrice Lecuru, Bertrand Dubois, Sarah Bétrian   +23 more
doaj   +1 more source

Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. [PDF]

, 2019
BackgroundWe previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy.
Demaria, Sandra, Dixit, Neha, Evensen, Erik, Formenti, Silvia C, Goldberg, Judith D, Hawtin, Rachael E, Lee, Percy, Li, Xiaochun, McBride, William H, Schaue, Dörthe, Vanpouille-Box, Claire   +10 more
core   +1 more source

Immunogenicity of targeted lentivectors [PDF]

, 2014
To increase the safety and possibly efficacy of HIV-1 derived lentivectors (LVs) as an anti-cancer vaccine, we recently developed the Nanobody (Nb) display technology to target LVs to antigen presenting cells (APCs).
Adotévi, Bennett, Bevan, Bhardwaj, Bhardwaj, Bhardwaj, Blander, Bonehill, Bonehill, Breckpot, Breckpot, Breckpot, Charleston, Chuah, Collins, Collins, Collins, Collins, Cosset, Diebold, Donckier, Eggermont, Enk, Figdor, Gajewski, Garcia, Groettrup, Inaba, Kast, Lahoutte, Lévy, McCullough, Medzhitov, Melief, Mellman, Mortha, Moser, Moser, Munn, Naldini, Neyns, Noguiez-Hellin, Nussenzweig, Palena, Raes, Reis e Sousa, Reiser, Reiser, Richardson, Romani, Roncarolo, Sakuma, Schroyens, Semesyuk, Song, Storm, Thielemans, Thielemans, Thielemans, Thielemans, Torretta, Turk, Van Kooyk, Wang, Wang, Yamaguchi, Yewdell, Yu   +67 more
core   +3 more sources